Dr. Marshall Schreeder

Chair, Serina Clinical Advisory Board

Dr. Schreeder is the Chair of the Serina Clinical Advisory Board. He is also Chair of the Clearview Cancer Institute (CCI), which serves as a clinical research site for patient participation and recruitment in a wide range of cancer trials in Alabama and on a national scale. He received his M.D. from Tulane University and completed his medical residency in Internal Medicine at Emory University. His Fellowship in Hematology and Oncology is from the University of Alabama Birmingham, and he is Board Certified in Hematology and Oncology. He has conducted clinical and epidemiological research in both cancer and infectious diseases over the course of his career, with the former as the primary focus. At Clearview Cancer Institute he has served as principle investigator, physician investigator, or sub-investigator on over 50 research trials and has served on advisory and ethics boards for various biomedical entities. Clearview Cancer Institute has and continues to serve as the initial site for the first, commercially available Biobank trial in the United States, enrolling over 2500 patients to the trial and providing a much-needed resource to the molecular and diagnostic research community across the globe.

Dr. Schreeder has served as the principle scientist on trials testing molecular diagnostics for breast, lung and cancer of unknown primary origin, as well as research trials treating difficult and aggressive diseases such as TNBC, pancreatic cancer, and advanced lung cancer. He, along with the co-investigators in the CCI, provide a wealth of expertise in oncology care, diagnostics and treatment, as well as molecular biology, genomics and genetics. In summary, his record as an investigator in research protocols and publications is extensive and distinguished, and he brings a wealth of insight to Serina’s clinical investigations.